288 related articles for article (PubMed ID: 24847085)
1. Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma.
Bartels U; Wolff J; Gore L; Dunkel I; Gilheeney S; Allen J; Goldman S; Yalon M; Packer RJ; Korones DN; Smith A; Cohen K; Kuttesch J; Strother D; Baruchel S; Gammon J; Kowalski M; Bouffet E
Neuro Oncol; 2014 Nov; 16(11):1554-9. PubMed ID: 24847085
[TBL] [Abstract][Full Text] [Related]
2. Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study.
Fleischhack G; Massimino M; Warmuth-Metz M; Khuhlaeva E; Janssen G; Graf N; Rutkowski S; Beilken A; Schmid I; Biassoni V; Gorelishev SK; Kramm C; Reinhard H; Schlegel PG; Kortmann RD; Reuter D; Bach F; Iznaga-Escobar NE; Bode U
J Neurooncol; 2019 May; 143(1):107-113. PubMed ID: 30830679
[TBL] [Abstract][Full Text] [Related]
3. Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature.
Kebudi R; Cakir FB; Bay SB; Gorgun O; Altınok P; Iribas A; Agaoglu FY; Darendeliler E
Childs Nerv Syst; 2019 Jan; 35(1):83-89. PubMed ID: 30417211
[TBL] [Abstract][Full Text] [Related]
4. Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood.
Massimino M; Biassoni V; Miceli R; Schiavello E; Warmuth-Metz M; Modena P; Casanova M; Pecori E; Giangaspero F; Antonelli M; Buttarelli FR; Potepan P; Pollo B; Nunziata R; Spreafico F; Podda M; Anichini A; Clerici CA; Sardi I; De Cecco L; Bode U; Bach F; Gandola L
J Neurooncol; 2014 Jun; 118(2):305-312. PubMed ID: 24696052
[TBL] [Abstract][Full Text] [Related]
5. Nimotuzumab as Additional Therapy for GLIOMA in Pediatric and Adolescent: A Systematic Review.
Parenrengi MA; Suryaningtyas W; Al Fauzi A; Hafid Bajamal A; Kusumastuti K; Utomo B; Muslim Hidayat Thamrin A; Sulistiono B
Cancer Control; 2022; 29():10732748211053927. PubMed ID: 35191733
[TBL] [Abstract][Full Text] [Related]
6. Nimotuzumab-vinorelbine combination therapy versus other regimens in the treatment of pediatric diffuse intrinsic pontine glioma.
Özkan A; Yağcı Küpeli B; Küpeli S; Sezgin G; Bayram İ
Childs Nerv Syst; 2024 Jun; 40(6):1671-1680. PubMed ID: 38478066
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.
Broniscer A; Jia S; Mandrell B; Hamideh D; Huang J; Onar-Thomas A; Gajjar A; Raimondi SC; Tatevossian RG; Stewart CF
Pediatr Blood Cancer; 2018 Jul; 65(7):e27035. PubMed ID: 29512900
[TBL] [Abstract][Full Text] [Related]
8. The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma.
Burzynski SR; Janicki TJ; Burzynski GS; Marszalek A
Childs Nerv Syst; 2014 Dec; 30(12):2051-61. PubMed ID: 24718705
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
DeWire M; Fuller C; Hummel TR; Chow LML; Salloum R; de Blank P; Pater L; Lawson S; Zhu X; Dexheimer P; Carle AC; Kumar SS; Drissi R; Stevenson CB; Lane A; Breneman J; Witte D; Jones BV; Leach JL; Fouladi M
J Neurooncol; 2020 Sep; 149(3):511-522. PubMed ID: 33034839
[TBL] [Abstract][Full Text] [Related]
10. A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study.
Macy ME; Kieran MW; Chi SN; Cohen KJ; MacDonald TJ; Smith AA; Etzl MM; Kuei MC; Donson AM; Gore L; DiRenzo J; Trippett TM; Ostrovnaya I; Narendran A; Foreman NK; Dunkel IJ
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28544128
[TBL] [Abstract][Full Text] [Related]
11. Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group.
Janssens GO; Gandola L; Bolle S; Mandeville H; Ramos-Albiac M; van Beek K; Benghiat H; Hoeben B; Morales La Madrid A; Kortmann RD; Hargrave D; Menten J; Pecori E; Biassoni V; von Bueren AO; van Vuurden DG; Massimino M; Sturm D; Peters M; Kramm CM
Eur J Cancer; 2017 Mar; 73():38-47. PubMed ID: 28161497
[TBL] [Abstract][Full Text] [Related]
12. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
Gururangan S; Chi SN; Young Poussaint T; Onar-Thomas A; Gilbertson RJ; Vajapeyam S; Friedman HS; Packer RJ; Rood BN; Boyett JM; Kun LE
J Clin Oncol; 2010 Jun; 28(18):3069-75. PubMed ID: 20479404
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.
Solomón MT; Selva JC; Figueredo J; Vaquer J; Toledo C; Quintanal N; Salva S; Domíngez R; Alert J; Marinello JJ; Catalá M; Griego MG; Martell JA; Luaces PL; Ballesteros J; de-Castro N; Bach F; Crombet T
BMC Cancer; 2013 Jun; 13():299. PubMed ID: 23782513
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma.
Burzynski SR; Janicki TJ; Weaver RA; Burzynski B
Integr Cancer Ther; 2006 Mar; 5(1):40-7. PubMed ID: 16484713
[TBL] [Abstract][Full Text] [Related]
16. Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial.
Souweidane MM; Kramer K; Pandit-Taskar N; Zhou Z; Haque S; Zanzonico P; Carrasquillo JA; Lyashchenko SK; Thakur SB; Donzelli M; Turner RS; Lewis JS; Cheung NV; Larson SM; Dunkel IJ
Lancet Oncol; 2018 Aug; 19(8):1040-1050. PubMed ID: 29914796
[TBL] [Abstract][Full Text] [Related]
17. Nimotuzumab for pediatric diffuse intrinsic pontine gliomas.
Massimino M; Bode U; Biassoni V; Fleischhack G
Expert Opin Biol Ther; 2011 Feb; 11(2):247-56. PubMed ID: 21171927
[TBL] [Abstract][Full Text] [Related]
18. [Nimotuzumab in combination with chemotherapy for patients with malignant gliomas].
Yang QY; Shen D; Sai K; Mu YG; Jiang XB; Zhang XH; Chen ZP
Zhonghua Zhong Liu Za Zhi; 2011 Mar; 33(3):232-5. PubMed ID: 21575527
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise?
Rizzo D; Scalzone M; Ruggiero A; Maurizi P; Attinà G; Mastrangelo S; Lazzareschi I; Ridola V; Colosimo C; Caldarelli M; Balducci M; Riccardi R
J Chemother; 2015 Feb; 27(2):106-10. PubMed ID: 25466729
[TBL] [Abstract][Full Text] [Related]
20. Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial.
McCrea HJ; Ivanidze J; O'Connor A; Hersh EH; Boockvar JA; Gobin YP; Knopman J; Greenfield JP
J Neurosurg Pediatr; 2021 Aug; 28(4):371-379. PubMed ID: 34359048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
